has elegantly demonstrated that NRF2 is a key suppressor of ILC2 activation, our study provides the missing upstream link, identifying melatonin, a canonical circadian hormone, as a critical activator of the NRF2-Glutathione axis in ILC2s (64)
This process is vital for maintaining brain health by clearing accumulated waste products and supporting neuronal function
Healthcare professionals should approach disclosures of combined peptide use with a non-judgemental but clinically thorough assessment, and provide harm-minimisation advice where appropriate
Prescription Required: Yes (must be administered by a qualified healthcare professional)
American Journal of Physiology-Cell Physiology
Ipamorelin was originally developed by company Novo Nordisk, and was investigated in phase II clinical trials by Helsinn Therapeutics for treatment of postoperative ileus